Wockhardt Limited
NSE: WOCKPHARMA BSE: WOCKPHARMA
NSE
1,350.80
34.90 (2.65%)
Prev Close
1315.9
Open Price
1390
Volume
478,479
Today Low / High
1330 / 1397.1
52 WK Low / High
1110.05 / 1868.8
Range
1,283 - 1,418
BSE
1,355.60
40.85 (3.11%)
Prev Close
1314.75
Open Price
1393.35
Volume
19,854
Today Low / High
1348.4 / 1395.4
52 WK Low / High
1109.6 / 1870
Range
1,288 - 1,423
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1350.8 (target range: 1,283 - 1,418), reflecting a change of 34.9 (2.65218%). On the BSE, it is listed at 1355.6 (target range: 1,288 - 1,423), showing a change of 40.85 (3.10705%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
03 Feb
1,390.00
-2.82%
02 Feb
1,348.60
-2.42%
01 Feb
1,371.00
-1.25%
30 Jan
1,365.00
1.26%
29 Jan
1,358.00
1.01%
28 Jan
1,351.00
0.42%
27 Jan
1,375.10
-1.93%
23 Jan
1,363.00
-0.84%
22 Jan
1,367.30
-0.50%
21 Jan
1,367.10
-1.35%
20 Jan
1,417.60
-2.93%
19 Jan
1,419.20
-0.11%
16 Jan
1,395.20
2.32%
14 Jan
1,387.60
0.54%
13 Jan
1,400.00
-0.89%
12 Jan
1,410.00
-1.15%
09 Jan
1,458.00
-3.71%
08 Jan
1,511.80
-3.53%
07 Jan
1,465.70
3.16%
06 Jan
1,452.40
0.92%
Wockhardt Limited Graph
Wockhardt Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Wockhardt Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,350.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,355.60 | 1,369.16 | 1,232.24 - 1,506.07 |
| 1,382.71 | 1,106.17 - 1,659.25 | ||
| 1,396.27 | 977.39 - 1,815.15 | ||
| Bearish Scenario | 1,355.60 | 1,342.04 | 1,207.84 - 1,476.25 |
| 1,328.49 | 1,062.79 - 1,594.19 | ||
| 1,314.93 | 920.45 - 1,709.41 |
Overview of Wockhardt Limited
ISIN
INE049B01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,189,143
Market Cap
219,575,667,970
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
1,561.26
DCF
-245
Financial Ratios Every Investor Needs
Stock Dividend of WOCKPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2016-11-17 | November 17, 16 | 9.21833 | 10 | 2016-11-19 | 2016-11-25 | 2016-10-28 |
| 2014-11-13 | November 13, 14 | 18.43666 | 20 | 2014-11-15 | 2014-12-02 | 2014-11-03 |
| 2014-02-17 | February 17, 14 | 4.60917 | 5 | 2014-02-19 | 2014-03-11 | 2014-02-10 |
| 2013-11-07 | November 07, 13 | 4.60917 | 5 | 2013-11-08 | 2013-11-24 | 2013-10-25 |
| 2013-08-22 | August 22, 13 | 4.60917 | 5 | 2013-08-23 | 2013-10-02 | 2013-05-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,035.00 Cr | 1,209.00 Cr | 1,826.00 Cr | 0.6016 | 119.00 Cr | 0.00 Cr | 1,053.63 Cr | -47.00 Cr | -3.00 | 360.00 Cr | -0.0155 |
| 2024-03-31 | 2,830.00 Cr | 1,232.00 Cr | 1,598.00 Cr | 0.5647 | 132.00 Cr | 0.00 Cr | 836.18 Cr | -463.00 Cr | -32.10 | 138.00 Cr | -0.1636 |
| 2023-03-31 | 2,657.00 Cr | 1,172.00 Cr | 1,485.00 Cr | 0.5589 | 141.00 Cr | 0.00 Cr | 705.98 Cr | -559.00 Cr | -38.80 | 42.00 Cr | -0.2104 |
| 2022-03-31 | 3,230.00 Cr | 1,349.00 Cr | 1,881.00 Cr | 0.5824 | 143.00 Cr | 0.00 Cr | 987.13 Cr | -244.00 Cr | -20.24 | 226.00 Cr | -0.0755 |
| 2021-03-31 | 2,708.00 Cr | 1,210.00 Cr | 1,498.00 Cr | 0.5532 | 172.00 Cr | 0.00 Cr | 533.00 Cr | 686.00 Cr | -24.89 | -143.00 Cr | 0.2533 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 191.00 Cr | 8,135.00 Cr | 3,478.00 Cr | 4,353.0000 Cr | 2,021.00 Cr | 1,830.00 Cr | 725.00 Cr | 2,231.00 Cr | 0.00 Cr | 66.00 Cr | 53.00 Cr | 2,042.0000 Cr |
| 2024-03-31 | 505.00 Cr | 7,649.00 Cr | 3,987.00 Cr | 3,359.0000 Cr | 2,356.00 Cr | 1,851.00 Cr | 642.00 Cr | 2,318.00 Cr | 104.00 Cr | 72.00 Cr | 17.00 Cr | 2,791.0000 Cr |
| 2023-03-31 | 90.00 Cr | 7,683.00 Cr | 4,021.00 Cr | 3,354.0000 Cr | 2,184.00 Cr | 2,094.00 Cr | 658.00 Cr | 2,436.00 Cr | 73.00 Cr | 78.00 Cr | 4.00 Cr | 3,435.0000 Cr |
| 2022-03-31 | 370.00 Cr | 8,243.00 Cr | 4,041.00 Cr | 3,849.0000 Cr | 2,198.00 Cr | 1,828.00 Cr | 769.00 Cr | 2,860.00 Cr | 68.00 Cr | 0.00 Cr | 18.00 Cr | 3,207.0000 Cr |
| 2021-03-31 | 232.25 Cr | 7,772.69 Cr | 4,012.44 Cr | 3,376.7600 Cr | 2,672.95 Cr | 2,440.70 Cr | 798.88 Cr | 2,914.26 Cr | 68.86 Cr | 0.00 Cr | -4.99 Cr | 3,118.2200 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -22.0000 Cr | -783.0000 Cr | 409.0000 Cr | -264.0000 Cr | -393.0000 Cr | 112.0000 Cr | -365.0000 Cr | -47.0000 Cr | -339.0000 Cr | 0.0000 Cr | -69.0000 Cr |
| 2024-03-31 | 219.0000 Cr | -137.0000 Cr | 334.0000 Cr | 3.0000 Cr | 415.0000 Cr | 505.0000 Cr | -59.0000 Cr | -463.0000 Cr | 143.0000 Cr | 0.0000 Cr | 8.0000 Cr |
| 2023-03-31 | 153.0000 Cr | -125.0000 Cr | -315.0000 Cr | -56.0000 Cr | -280.0000 Cr | 90.0000 Cr | -209.0000 Cr | -624.0000 Cr | -336.0000 Cr | 0.0000 Cr | 141.0000 Cr |
| 2022-03-31 | 413.0000 Cr | -201.0000 Cr | -71.0000 Cr | 201.0000 Cr | 138.0000 Cr | 370.0000 Cr | -212.0000 Cr | -411.0000 Cr | -555.0000 Cr | -2.0000 Cr | 30.0000 Cr |
| 2021-03-31 | -287.3200 Cr | 1,470.1000 Cr | -1,170.8200 Cr | -453.0500 Cr | 12.9100 Cr | 232.2500 Cr | -165.7300 Cr | 915.8500 Cr | -815.0000 Cr | -0.5300 Cr | -106.6800 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 782.00 Cr | 472.00 Cr | 310.00 Cr | 0.3964 | 107.00 Cr | 78.00 Cr | 4.80 | 199.00 Cr | 0.0997 |
| 2025-06-30 | 738.00 Cr | 264.00 Cr | 474.00 Cr | 0.6423 | 303.00 Cr | -90.00 Cr | -5.53 | 84.25 Cr | -0.1220 |
| 2025-03-31 | 766.00 Cr | 337.00 Cr | 429.00 Cr | 0.5601 | 141.63 Cr | -25.00 Cr | -1.57 | 88.25 Cr | -0.0326 |
| 2024-12-31 | 721.00 Cr | 262.00 Cr | 459.00 Cr | 0.6366 | 295.00 Cr | 14.00 Cr | 0.91 | 81.00 Cr | 0.0194 |
| 2024-09-30 | 809.00 Cr | 297.00 Cr | 512.00 Cr | 0.6329 | 351.00 Cr | -22.00 Cr | -1.47 | 129.50 Cr | -0.0272 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 234.00 Cr | 696.00 Cr | 930.00 Cr | 536.00 Cr | 866.00 Cr | 2,701.00 Cr | 2,256.00 Cr | 8,533.00 Cr | 3,657.00 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 588.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,657.00 Cr |
| 2025-03-31 | 191.00 Cr | 422.00 Cr | 613.00 Cr | 661.00 Cr | 725.00 Cr | 2,465.00 Cr | 2,231.00 Cr | 8,135.00 Cr | 3,478.00 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 223.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,713.00 Cr |
| 2024-09-30 | 175.00 Cr | 83.00 Cr | 258.00 Cr | 695.00 Cr | 657.00 Cr | 2,008.00 Cr | 2,287.00 Cr | 7,588.00 Cr | 3,875.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -90.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -25.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 14.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -22.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -14.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-03-08 | March 08, 22 | 217:200 |
| 2004-04-28 | April 28, 04 | 3:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,707.60 | ₹4,097,104,394,772.00 | ₹4,557,769.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,272.00 | ₹1,665,018,933,760.00 | ₹289,506.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,036.90 | ₹1,366,270,396,736.00 | ₹286,467.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,235.30 | ₹1,028,471,485,107.00 | ₹956,827.00 |
| Lupin Limited | LUPIN | ₹2,194.20 | ₹1,002,308,365,800.00 | ₹620,016.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹901.15 | ₹906,767,760,089.00 | ₹423,303.00 |
| Mankind Pharma Limited | MANKIND | ₹2,168.40 | ₹895,126,518,125.00 | ₹336,863.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,236.00 | ₹717,870,806,028.00 | ₹1,401,552.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,738.00 | ₹686,063,970,000.00 | ₹96,194.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,967.50 | ₹555,230,091,708.00 | ₹269,835.00 |
| Laurus Labs Limited | LAURUSLABS | ₹976.55 | ₹527,196,945,152.00 | ₹1,079,882.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,444.30 | ₹366,425,002,057.00 | ₹73,481.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,879.30 | ₹359,727,142,183.00 | ₹63,910.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,897.50 | ₹304,425,412,500.00 | ₹105,241.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,507.50 | ₹285,780,604,050.00 | ₹78,472.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,351.70 | ₹219,640,664,837.00 | ₹477,810.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,715.50 | ₹217,887,500,000.00 | ₹3,219.00 |
| Eris Lifesciences Limited | ERIS | ₹1,431.00 | ₹194,926,371,021.00 | ₹16,896.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,419.00 | ₹172,164,280,491.00 | ₹20,874.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.95 | ₹155,275,039,804.00 | ₹17,361.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹979.90 | ₹155,186,516,065.00 | ₹108,835.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹854.05 | ₹152,968,784,474.00 | ₹417,943.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.70 | ₹147,173,578,758.00 | ₹163,245.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,830.60 | ₹139,147,010,698.00 | ₹35,647.00 |
| Granules India Limited | GRANULES | ₹572.35 | ₹138,891,439,603.00 | ₹376,351.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹951.35 | ₹116,764,893,600.00 | ₹40,499.00 |
| Viyash Scientific Limited | VIYASH | ₹216.00 | ₹94,220,400,744.00 | ₹1,123,427.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,295.00 | ₹87,893,727,690.00 | ₹13,037.00 |
| Strides Pharma Science Limited | STAR | ₹861.80 | ₹79,434,444,925.00 | ₹174,461.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹788.05 | ₹71,434,600,037.00 | ₹103,646.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹452.55 | ₹69,286,336,348.00 | ₹90,762.00 |
| FDC Limited | FDC | ₹381.60 | ₹62,128,328,054.00 | ₹29,678.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹300.65 | ₹58,801,672,980.00 | ₹284,714.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.67 | ₹46,624,016,548.00 | ₹3,535,043.00 |
| Innova Captab Limited | INNOVACAP | ₹720.05 | ₹41,204,810,126.00 | ₹42,280.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹401.65 | ₹36,658,595,500.00 | ₹132,983.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹327.10 | ₹35,642,538,182.00 | ₹23,293.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹684.35 | ₹34,709,619,507.00 | ₹34,343.00 |
| Suven Life Sciences Limited | SUVEN | ₹148.17 | ₹33,704,822,580.00 | ₹349,103.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,986.10 | ₹32,848,137,692.00 | ₹7,446.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹310.30 | ₹31,117,661,612.00 | ₹26,127.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹398.55 | ₹28,060,211,663.00 | ₹31,382.00 |
Key Executives
Founder & Executive Chairman
Habil Fakhruddin Khorakiwala
Gender: Not Specified
Year Born: 1941
Executive Director
Huzaifa Habil Khorakiwala
Gender: Not Specified
Year Born: 1971
MD & Executive Director
Murtaza Habil Khorakiwala
Gender: Not Specified
Year Born: 1973
Chief Scientific Officer
Sachin Bhagwat
Gender: Not Specified
Year Born:
Senior Vice President of Business Development
Anil V. Kamath
Gender: male
Year Born: 1951
Chief Financial Officer
Deepak Madnani
Gender: male
Year Born:
President of Supply Chain
Prakash Gupta
Gender: male
Year Born:
Head of Human Resource
Satej Mehta
Gender: male
Year Born:
Head of Global Regulatory Affairs
Zoher T. Sihorwala
Gender: male
Year Born: 1970
Senior Vice President of Legal
Debolina Partap
Gender: female
Year Born:
FAQs about Wockhardt Limited
Who is the CEO of the company?
The CEO is Habil Fakhruddin Khorakiwala.
What is the current market price of the stock?
The current price is ₹1,351.30.
What is the 52-week price range?
The range is ₹1110.05-1868.8.
What is the market capitalization of the company?
The market capitalization is ₹21,957.57 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -954.68.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Wockhardt Limited (ISIN: INE049B01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹21,957.57 crores and an average daily volume of 1,189,143 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.